There is a growing body of evidence that TERT-promoter genes are present in ACC patients without MYB/MYBL1 fusions or NOTCH pathway mutations, indicating alternative tumorigenesis pathways [30]. This evidence concerns the gene TERT and adrenal cortex carcinoma.